NVOS (Novo Integrated Sciences) Cash-to-Debt : 0.34 (As of May. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Novo Integrated Sciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Novo Integrated Sciences's cash to debt ratio for the quarter that ended in May. 2024 was 0.34.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Novo Integrated Sciences couldn't pay off its debt using the cash in hand for the quarter that ended in May. 2024.

The historical rank and industry rank for Novo Integrated Sciences's Cash-to-Debt or its related term are showing as below:

NVOS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 0.53 Max: No Debt
Current: 0.34

During the past 13 years, Novo Integrated Sciences's highest Cash to Debt Ratio was No Debt. The lowest was 0.00. And the median was 0.53.

NVOS's Cash-to-Debt is ranked worse than
65.62% of 666 companies
in the Healthcare Providers & Services industry
Industry Median: 0.76 vs NVOS: 0.34

Novo Integrated Sciences Cash-to-Debt Historical Data

The historical data trend for Novo Integrated Sciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Novo Integrated Sciences Cash-to-Debt Chart

Novo Integrated Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Cash-to-Debt

Get a 7-Day Free Trial

0.50

0.47

0.61

0.17

0.09

Novo Integrated Sciences Quarterly Data
	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24
Cash-to-Debt	Get a 7-Day Free Trial															0.10	0.09	0.35	0.12	0.34

Competitive Comparison of Novo Integrated Sciences's Cash-to-Debt

For the Medical Care Facilities subindustry, Novo Integrated Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novo Integrated Sciences's Cash-to-Debt Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Novo Integrated Sciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Novo Integrated Sciences's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Novo Integrated Sciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Novo Integrated Sciences's Cash to Debt Ratio for the fiscal year that ended in Aug. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.416	/	(2.713	+	1.759)
	=	0.09

Novo Integrated Sciences's Cash to Debt Ratio for the quarter that ended in May. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.54	/	(2.904	+	1.598)
	=	0.34

Novo Integrated Sciences (OTCPK:NVOS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Novo Integrated Sciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Novo Integrated Sciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Integrated Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Novo Integrated Sciences Inc (OTCPK:NVOS) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

11120 NE 2nd Street, Suite 100, Bellevue, WA, USA, 98004

Website

https://www.novointegrated.com

Novo Integrated Sciences Inc is a medical care company. It provides specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, neurological functions, kinesiology, and others. It has two reportable segments: healthcare services and product sales. Healthcare services generate the majority of revenue.

Executives

Sarfaraz Ali	director	C/O NOVO INTEGRATED SCIENCES, INC.,, 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Robert Letterio Oliva	director	115 BELFIELD RD, TORONTO A6 L0J 1C0
Sterling M. Jimenez	officer: Principal Financial Officer	C/O NOVO INTEGRATED SCIENCES, INC.,, 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Michael Ross Pope	director	1045 PROGRESS CIRCLE, LAWRENCEVILLE, GEORGIA GA 30043
Alex Flesias	director	41 LANDMARK COURT, UNIONVILLE A6 L3R 9N7
Michael Joseph Gaynor	director	49 BALMORAL ST, KEMPTVILLE A6 K0G 1J0
Robert Mattacchione	director, 10 percent owner, officer: Chief Executive Officer	79 SELVAPIANO CRES, WOODBRIDGE A6 L4H 0X1
Pierre Joseph Dalcourt	director, 10 percent owner	35 BRYANT ST , BOX 2230, HEARST A6 P0L 1N0
Christopher Mehlin David	director, officer: President	10425 SE 22ND ST., BELLEVUE WA 98004
Thomas Edward Bray	officer: Principal Financial Officer	C/O NOVO INTEGRATED SCIENCES, INC., 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Rebecca Aw Mcdonald	officer: Chief Accounting Officer	1301 INTERNATIONAL SPEEDWAY BLVD., DELAND FL 32724
James Jr Teters	director	1200 FLIGHTLINE BLVD, STE 5, DELAN FL 32724
Phyllis Rouse	officer: secretary	1200 FLIGHLINE BLVD,, SUITE 5, DELAND FL 32724
Jay Hilden	officer: President & CEO	1200 FLIGHLINE BLVD,, SUITE 5, DELAND FL 32724
Robert Adamo	director	1200 FLIGHTLINE BOULEVARD, SUITE 5, DELAND FL 32724